Welcome to
Sysmex Flow Cytometry Other European Country!

For ordering please make sure you are in your local shop.
If you are from Other European Country then please continue.
Otherwise please go to your country.

Go to my country Continue

Article successfully added.

CyFlow™ CD23 FITC

CyFlow™ CD23 FITC
Antigen: CD23
Alternative Name: BLAST-2, FcɛRII
Clone: EBVCS-5
Application: Flow cytometry
Format/Fluorochrome: FITC
Laser: Blue
Target Species: Human
Field of Interest: Immunophenotyping
Species of Origin: Mouse
Regulatory Status: RUO
Clonality: monoclonal
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Isotype: IgG1
Order number: CS137840

For Research Use Only
Not for use in diagnostic or therapeutic procedures.

Quantity 100 tests Volume 0.4 Immunogen EBV-transformed human cells Background... more
CyFlow™ CD23 FITC
Quantity100 tests
ImmunogenEBV-transformed human cells
Background InformationCD23 (Fc ε RII), the low affinity IgE receptor, is a 45 kDa type II membrane glycoprotein expressed more or less on eosinophils, follicular dendritic cells, Langerhans cells, mature B cells (mainly upon activation), EBV-transformed lymphoblasts, monocytes, and subpopulation of platelets. A soluble form of 37 kDa and other its fragments were also described. CD23 mediates IgE-dependent cytotoxicity by eosinophils and macrophages, and downregulates IgE secretion in response to high levels of IgE, involving release of pro-inflammatory cytokines.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Ling NR, Stevenson FK, Brown B: Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL). Clin·Exp·Immunol. 1991·Dec; 86(3):360‑6. <·PMID:·1721010·> | Yamaoka KA, Arock M, Issaly F, Dugas N, Le Goff L, Kolb JP: Granulocyte macrophage colony stimulating factor induces Fc epsilon RII/CD23 expression on normal human polymorphonuclear neutrophils. Int·Immunol. 1996·Apr; 8(4):479‑90. <·PMID:·8722638·> | Rumi C, Rutella S, Leone G, Bonini S: Fc‑RII/CD23 receptor on circulating human eosinophils. Blood. 1998·Apr·1; 91(7):2621‑2. <·PMID:·9516167·> | Belleau JT, Gandhi RK, McPherson HM, Lew DB: Research upregulation of CD23 (FcepsilonRII) expression in human airway smooth muscle cells (huASMC) in response to IL‑4, GM‑CSF, and IL‑4/GM‑CSF. Clin·Mol·Allergy. 2005·May·20; 3:6. <·PMID:·15907205·> | Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin·Cancer·Res. 2007·Aug·1; 13(15‑1):4448‑55. <·PMID:·17671129·>